Literature DB >> 16696408

Survival rate of recurrent cervical cancer patients.

S Poolkerd1, S Leelahakorn, S Manusirivithaya, S Tangjitgamol, T Thavaramara, P Sukwattana, K Pataradule.   

Abstract

OBJECTIVES: To determine the survival rate of recurrent cervical cancer patients and factors influencing survival. MATERIAL AND
METHOD: The subjects were identified from the Gynecologic Oncology Unit tumor registry record The pathological, clinical data including the follow-up information of recurrent cervical cancer patients who were treated in the Gynecologic Oncology Unit, Bangkok Metropolitan Administration Medical College and Vajira Hospital between 1992 and 2003 were retrospective reviewed.
RESULTS: During the study period, 144 recurrent cervical cancer patients were identified. Mean age of the patients was 52 years. The median time from complete primary treatment to disease recurrence was 14.8 months. Seventy-two patients (50%) had previous stage III disease. The most common histopalogy was squamous cell carcinoma (72.9%). Approximately half of the recurrences were local (73 patients or 50.7%) and distal recurrences were encountered in 71 patients or 49.3%. Overall 109 patients received treatmentfor their recurrences, i.e. radiation alone (55 patients, 38.2%), chemotherapy (31 patients, 21.5%), chemotherapy and radiation (18 patients, 12.5%), surgery (5 patients, 3.5%), and 35 patients (24.3%) received only supportive treatment. Two-year survival rate of the group was 18.5%. Median survival was 8 months (95%CI, 7-10 months). The patients with only local recurrence had a 2-year survival rate of 22.2% compared to 14.6% in those with distant recurrence. (p = 0.245). Two-year survival rate of those who received any kind of treatment was 22.4% compared to 4.0% in those who received only supportive treatment (p = 0.014 and 0.017 in univariable and multivariable analysis respectively).
CONCLUSION: Survival rate of recurrent cervical cancer was low, especially in those who received only supportive treatment.

Entities:  

Mesh:

Year:  2006        PMID: 16696408

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  6 in total

1.  NUCKS1 overexpression is a novel biomarker for recurrence-free survival in cervical squamous cell carcinoma.

Authors:  Lina Gu; Bairong Xia; Lili Zhong; Yuan Ma; Lei Liu; Liping Yang; Ge Lou
Journal:  Tumour Biol       Date:  2014-05-13

2.  Phosphorylated c-Src is a novel predictor for recurrence in cervical squamous cell cancer patients.

Authors:  Teng Hou; Juan Xiao; Huiting Zhang; Haifeng Gu; Yanling Feng; Jundong Li
Journal:  Int J Clin Exp Pathol       Date:  2013-05-15

Review 3.  Clostridium perfringens enterotoxin (CPE) and CPE-binding domain (c-CPE) for the detection and treatment of gynecologic cancers.

Authors:  Jonathan D Black; Salvatore Lopez; Emiliano Cocco; Carlton L Schwab; Diana P English; Alessandro D Santin
Journal:  Toxins (Basel)       Date:  2015-04-01       Impact factor: 4.546

4.  Indicators of survival and prognostic factors in women treated for cervical cancer at a tertiary care center in Saudi Arabia.

Authors:  Nisreen Anfinan; Khalid Sait
Journal:  Ann Saudi Med       Date:  2020-02-06       Impact factor: 1.526

5.  Identifying Molecular Changes in Early Cervical Cancer Samples of Patients That Developed Metastasis.

Authors:  Vera de Geus; Patricia C Ewing-Graham; Willem de Koning; Maurits N C de Koning; Thierry P P van den Bosch; Alex L Nigg; Casper H J van Eijck; Marta Jozwiak; Heleen J van Beekhuizen; Dana A M Mustafa
Journal:  Front Oncol       Date:  2022-01-11       Impact factor: 6.244

6.  Increased expression of SRPK1 (serine/arginine-rich protein-specific kinase 1) is associated with progression and unfavorable prognosis in cervical squamous cell carcinoma.

Authors:  Zhanfei Dong; Xuezhi Chang; Li Xie; Yina Wang; Youxiang Hou
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.